Terns Pharmaceuticals Inc
NASDAQ:TERN

Watchlist Manager
Terns Pharmaceuticals Inc Logo
Terns Pharmaceuticals Inc
NASDAQ:TERN
Watchlist
Price: 7.08 USD 11.32% Market Closed
Market Cap: 601.4m USD
Have any thoughts about
Terns Pharmaceuticals Inc?
Write Note

Terns Pharmaceuticals Inc
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Terns Pharmaceuticals Inc
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Terns Pharmaceuticals Inc
NASDAQ:TERN
Cash Taxes Paid
$28k
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Cash Taxes Paid
$3.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Cash Taxes Paid
$3.8B
CAGR 3-Years
1%
CAGR 5-Years
-4%
CAGR 10-Years
4%
Merck & Co Inc
NYSE:MRK
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Terns Pharmaceuticals Inc
Glance View

Market Cap
601.2m USD
Industry
Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.

TERN Intrinsic Value
3.1 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Terns Pharmaceuticals Inc's Cash Taxes Paid?
Cash Taxes Paid
28k USD

Based on the financial report for Dec 31, 2023, Terns Pharmaceuticals Inc's Cash Taxes Paid amounts to 28k USD.

What is Terns Pharmaceuticals Inc's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 3Y
-46%

The average annual Cash Taxes Paid growth rates for Terns Pharmaceuticals Inc have been -46% over the past three years .

Back to Top